Medivir have agreed with Lonza to manufacture a fostrox GMP campaign, to be tested in 2L HCC with intent to commercialize via accelerated approval

STOCKHOLM, Dec. 13, 2023 /PRNewswire/ — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that it has signed an agreement with Lonza for the manufacture of a new GMP…